Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Signs of Growth in Prescribing SGLT-2 Inhibitors with Favorable Environment Change
November 30, 2016
- Shionogi Says UK Court Finds Its HIV Drug Patent Invalid, Set to Challenge Ruling
November 29, 2016
- Santen Eyes US Filing for Opsiria Early Next Year
November 29, 2016
- Chugai Licenses Class I PI3K Inhibitor to German Drug Maker
November 29, 2016
- Ono to Offer New Invoice Prices for Opdivo Early on to Avoid Distribution Confusion
November 29, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
November 28, 2016
- Shionogi Set to Go Global with Botulinum Toxin, Gets Rights from Tokushima Univ.
November 25, 2016
- CSL Behring to Enter Japanese Hemophilia Market with Idelvion
November 25, 2016
- MSD to Distribute Bayer’s Adempas from Next Year
November 25, 2016
- Ninlaro Earns Conditional Approval in Europe: Takeda
November 25, 2016
- Gynecologist Calls for Correct Understanding of Hormonal Products
November 24, 2016
- 27 Japan Drug Makers Eke Out Profit despite Logging Lower Sales on FX, Price Cuts: Jiho Tally
November 24, 2016
- Empliciti “Extremely Promising” in the Treatment of Multiple Myeloma: Hematologist
November 24, 2016
- Fujifilm Hooks Up with China Resources in Healthcare
November 22, 2016
- Taltz Finally Makes it to Japan Market after Pricing Flap
November 22, 2016
- Empliciti, Batch of Other Drugs Go on Sale in Japan
November 21, 2016
- 3 Japan Generic Majors See Subdued Sales Rise in April-September
November 21, 2016
- Invalidation Ruling for Evista Upheld: Sawai
November 21, 2016
- Eisai’s BACE Inhibitor Gets FDA’s Fast-Track Status
November 21, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…